funding · SE · 29 JUN 2021

SAGA Diagnostics raised a SEK 106 million (about EUR 10.5 million) Series A2 round led by Segulah Medical Acceleration and the Sciety investment syndicate with support from existing shareholder Hadean Ventures, to commercialize its liquid biopsy cancer tests. This predates the April 2026 Foundation Medicine/Roche acquisition already on record.

SAGA Diagnostics · EUR 10.4M · Series A